# EDGAR Filing Document

**Accession Number:** 0001174940
**File Stem:** 0000000000-23-000591
**Filing Date:** 2023-1
**Character Count:** 3190
**Document Hash:** b4c63e2f1e1a820206175fa0c0b2bc1a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-000591.hdr.sgml**: 20230223

**ACCESSION NUMBER**: 0000000000-23-000591

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230119

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ORAGENICS INC
- **CENTRAL INDEX KEY:** 0001174940
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 593410522
- **STATE OF INCORPORATION:** FL
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 4902 EISENHOWER BLVD
- **STREET 2:** SUITE 125
- **CITY:** TAMPA
- **STATE:** FL
- **ZIP:** 33634
- **BUSINESS PHONE:** 8132867900

**MAIL ADDRESS:**
- **STREET 1:** 4902 EISENHOWER BLVD
- **STREET 2:** SUITE 125
- **CITY:** TAMPA
- **STATE:** FL
- **ZIP:** 33634

## Text-Extract

```

United States securities and exchange commission logo

                          January 19, 2023

       Kimberly Murphy
       Chief Executive Officer
       ORAGENICS INC
       4902 Eisenhower Boulevard, Suite 125
       Tampa, FL 33634

                                                        Re: ORAGENICS INC
                                                            Registration
Statement on Form S-3
                                                            Filed January 13,
2023
                                                            File No. 333-269225

       Dear Kimberly Murphy:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Lauren
Hamill at 303-844-1008 with any questions.

                          Sincerely,

                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Mark Catchur

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

January 19, 2023

Kimberly Murphy
Chief Executive Officer
ORAGENICS INC
4902 Eisenhower Boulevard, Suite 125
Tampa, FL 33634

Re: ORAGENICS INC
Registration Statement on Form S-3
Filed January 13, 2023
File No. 333-269225

Dear Kimberly Murphy:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Lauren Hamill at 303-844-1008 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Mark Catchur